Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) saw unusually-high trading volume on Thursday . Approximately 107,552 shares were traded during trading, a decline of 19% from the previous session’s volume of 132,895 shares.The stock last traded at $9.08 and had previously closed at $9.32.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Finally, Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy”.
Check Out Our Latest Stock Analysis on SGIOY
Shionogi & Co., Ltd. Unsponsored ADR Stock Up 0.2%
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.18 by $0.18. The company had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.47%. As a group, sell-side analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current year.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.
Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.
Featured Articles
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Chewy’s Sell-Off Puts Its Recurring Revenue Story Back on Trial for Investors
- Insider Sales Eclipse $450M Across 3 AI Winners, With NVIDIA Leading the Pack
- GameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks Stronger
- Why Braze’s Guidance Miss May Be a Gift for Investors
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
